| dbo:abstract
|
- CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba. There are agreements in place to test it in the United States, Japan, and some European countries. It is currently available in Cuba, Colombia, Bosnia and Herzegovina, Peru and Paraguay. In October 2015 Serbia's Institute of Virology, Vaccines and Sera (AKA Torlak Institute) signed a memorandum for use in 30 patients as part of a study. CimaVax is relatively cheap to produce and store, and has low toxicity. Side effects of the vaccine appear to be mild, and include chills, fever, and feeling sick. (en)
- CimaVax-EGF es una vacuna utilizada para tratar el carcinoma pulmonar no microcítico (CPNM). La vacuna hace blanco específico en la proteína natural Nepidermina (EGF en inglés).Esta vacuna ha prolongado la vida de los pacientes, especialmente de los menores de 60 años, con una supervivencia media de 18 meses en los vacunados en comparación con los 7 meses para los no vacunados. Los efectos secundarios de la vacuna parecen ser leves e incluyen escalofríos, fiebre, y sensación de resfrío. (es)
|
